Abstract
To review the interaction between melatonin and the dopaminergic system in the hypothalamus and striatum and its potential clinical use in dopamine-related disorders in the central nervous system. Medline-based search on melatonin–dopamine interactions in mammals. Melatonin, the hormone produced by the pineal gland atnight, influences circadian and seasonal rhythms, most notably the sleep–wake cycle and seasonal reproduction. The neurochemical basis of these activities is not understood yet. Inhibition of dopamine release by melatonin has been demonstrated in specific areas of the mammalian central nervous system (hypothalamus, hippocampus, medulla-pons, and retina). Antidopaminergic activities of melatonin have been demonstrated in the striatum. Dopaminergic transmission has a pivotal role in circadian entrainment of the fetus, in coordination of body movement and reproduction. Recent findings indicate that melatonin may modulate dopaminergic pathways involved in movement disorders in humans. In Parkinson patients melatonin may, on the one hand, exacerbate symptoms (because of its putative interference with dopamine release) and, on the other, protect against neurodegeneration (by virtue of its antioxidant properties and its effects on mitochondrial activity). Melatonin appears tobe effective in the treatment of tardive dyskinesia, a severe movement disorder associated with long-term blockade of the postsynaptic dopamine D2 receptor by antipsychotic drugs in schizophrenic patients. The interaction of melatonin with the dopaminergic system may play a significant role in the nonphotic and photic entrainment of the biological clock as well as in the fine-tuning of motor coordination in the striatum. These interactions and the antioxidant nature of melatonin may be beneficial in the treatment of dopamine-related disorders.
Similar content being viewed by others
REFERENCES
Adler, L. A.,Edson, R.,Lavori, P.,Peselow, E.,Duncan, E.,Rosenthal, M., andRotrosen, J. (1998). Long-term treatment effects of vitamin E for tardive dyskinesia. Biol. Psychiatry 43: 868-872.
Alexiuk, N. A.,Uddin, M., andVriend, J. (1996). Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male Syrian hamsters. Life Sci. 59: 687-694.
Alexiuk, N. A., andVriend, J. P. (1993). Melatonin reduces dopamine content in the neurointermediate lobe of male Syrian hamsters. Brain Res. Bull. 32: 433-436.
Barak, Y.,Swartz, M.,Shamir, E.,Stein, D., andWeizman, A. (1998). Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: A statistical meta-analysis. Ann. Clin. Psychiatry 10: 101-105.
Cagnacci, A.,Elliott, J. A., andYen, S. S. (1992). Melatonin: A major regulator of the circadian rhythm of core temperature in humans. J. Clin. Endocrinol. Metab. 75: 447-452.
Cajochen, C.,Krauchi, K.,von Arx, M. A.,Mori, D.,Graw, P., andWirz-Justice, A. (1996). Daytime melatonin administration enhances sleepiness and theta/alpha activity in the waking EEG. Neurosci. Lett. 207: 209-213.
Cardoso, F., andJankovic, J. (1997). Dystonia and dyskinesia. Psychiatr. Clin. N. Am. 20: 821-838.
Coon, S. L.,Roseboom, P. H.,Baler, R.,WWeller, J. L.,Namboodiri, M. A.,Koonin, E. V., andKlein, D. C. (1995). Pineal serotonin N-acetyltransferase: Expression cloning and molecular analysis. Science 270: 1681-1683.
Cote, L., andCrutcher, M. (1991). The basal ganglia. In Kandel, E. R.,Scwartz, J. H., andJessel, T. M. (eds.), Principles of Neural Science, Appleton and Young, New York, pp. 647-659.
Dabbeni-Sala, F.,Di Santo, S.,Franceschini, D.,Skaper, S. D., andGiusti, P. (2001). Melatonin protects against 6-OHDA-induced neurotoxicity in rats:Arole for mitochondrial complex I activity. FASEB J. 15: 164-170.
Deacon, S., andArendt, J. (1996). Adapting to phase shifts, II. Effects of melatonin and conflicting light treatment. Physiol. Behav. 59: 675-682.
Di Chiara, G.,Morelli, M., and Consolo, S. (1994). Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 17: 228-233.
Dunlap, J. C. (1999). Molecular bases for circadian clocks. Cell 96: 271-290.
Ebadi, M., andGovitrapong, P. (1986). Neural pathways and neurotransmitters affecting melatonin synthesis. J. Neural. Transm. Suppl. 21: 125-155.
Escames, G.,Acuna Castroviejo, D., andVives, F. (1996). Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. Neuroreport 7: 597-600.
Escames, G.,Macias, M.,Leon, J.,Garcia, J.,Khaldy, H.,Martin, M.,Vives, F., andAcuna-Castroviejo, D. (2001). Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum. J. Neuroendocrinol. 13: 459-466.
Exposito, I.,Mora, F.,Zisapel, N., andOaknin, S. (1995). The modulatory effect of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus during ageing. Neuroreport 6: 2399-2403.
Forsling, M. L.,Wheeler, M. J., andWilliams, A. J. (1999). The effect of melatonin administration on pituitary hormone secretion in man. Clin. Endocrinol. (Oxf). 51: 637-542.
Fujieda, H.,Scher, J.,Hamadanizadeh, S. A.,Wankiewicz, E.,Pang, S. F., andBrown, G. M. (2000). Dopaminergic and GABAergic amacrine cells are direct targets of melatonin: Immunocytochemical study of mt1 melatonin receptor in guinea pig retina. Vis. Neurosci. 17: 63-70.
Garfinkel, D.,Laudon, M.,Nof, D., andZisapel, N. (1995). Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346: 541-544.
Gastel, J. A.,Roseboom, P. H.,Rinaldi, P. A.,W eller, J. L., andKlein, D. C. (1998). Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation. Science 279: 1358-1360.
Grosse, J., andDavis, F. C. (1999). Transient entrainment of a circadian pacemaker during development by dopaminergic activation in Syrian hamsters. Brain Res. Bull. 48: 185-194.
Hastings, M. (1998). The brain, circadian rhythms, and clock genes. BMJ. 317: 1704-1707.
Hedlund, L.,Lischko, M. M.,Rollag, M.D., andNiswender, G.D. (1977). Melatonin: Daily cycle in plasma and cerebrospinal fluid of calves. Science 195: 686-687.
Hunt, A. E.,Al-Ghoul, W. M.,Gillette, M. U., andDubocovich, M. L. (2001). Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am.J. Physiol. Cell Physiol. 280: C110-C118.
Jaliffa, C. O.,Lacoste, F. F.,Llomovatte, D.W.,Sarmiento, M. I., andRosenstein, R. E. (2000). Dopamine decreases melatonin content in golden hamster retina. J. Pharmacol. Exp. Ther. 293: 91-95.
Joo, W. S.,Jin, B. K.,Park, C. W.,Maeng, S. H., andKim, Y. S. (1998). Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport 9: 4123-4126.
Kim, Y. S.,Joo, W. S.,Jin, B. K.,Cho, Y. H.,Baik, H. H., andPark, C. W. (1998). Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 9: 2387-2390.
Krauchi, K.,Cajochen, C.,Werth, E., andWirz-Justice, A. (2000). Functional link between distal vasodilation and sleep-onset latency? Am. J. Physiol. Regul. Integr. Comp. Physiol. 278: R741-R748.
Laudon, M., andZisapel, N. (1986). Characterization of central melatonin receptors using 125I-melatonin. FEBS Lett. 197: 9-12.
Leon, J.,Vives, F.,Crespo, E.,Camacho, E.,Espinosa, A.,Gallo, M. A.,Escames, G., andAcuna-Castroviejo, D. (1998). Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivatives. J. Neuroendocrinol. 10: 297-302.
Lewy, A. J.,Ahmed, S.,Jackson, J. M., andSack, R. L. (1992). Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol. Int. 9: 380-392.
Lewy, A. J.,Ahmed, S., andSack, R. L. (1996). Phase shifting the human circadian clock using melatonin. Behav. Brain Res. 73: 131-134.
Lincoln, G. (1999). Melatonin modulation of prolactin and gonadotrophin secretion. Systems ancient and modern. Adv. Exp. Med. Biol. 460: 137-153.
Liu, C.,Weaver, D. R.,Jin, X.,Shearman, L. P.,Pieschl, R. L.,Gribkoff, V. K., andReppert, S. M. (1997). Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 19: 91-102.
Lockley, S. W.,Skene, D. J.,Tabandeh, H.,Bird, A. C.,Defrance, R., andArendt, J. (1997). Relationship between napping and melatonin in the blind. J. Biol. Rhythms 12: 16-25.
McArthur, A. J.,Hunt, A. E., andGillette, M. U. (1997). Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology 138: 627-634.
Misztal, T.,Romanowicz, K., andBarcikowski, B. (1997). Natural and melatonin-stimulated changes in the circadian rhythm of prolactin secretion in the ewe during seasonal anestrus. Neuroendocrinology 66: 360-367.
Naitoh, N.,Watanabe, Y.,Matsumura, K.,Murai, I.,Kobayashi, K.,Imai-Matsumura, K.,Ohtuka, H.,Takagi, K.,Miyake, Y., andSatoh, K. (1998). Alteration by maternal pinealectomy of fetal and neonatal melatonin and dopamine D1 receptor binding in the suprachiasmatic nuclei. Biochem. Biophys. Res. Commun. 253: 850-854.
Nosjean, O.,Ferro, M.,Coge, F.,Beauverger, P.,Henlin, J. M.,Lefoulon, F.,Fauchere, J. L.,Delagrange, P.,Canet, E., andBoutin, J. A. (2000). Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 275: 31311-31317.
Ortiz, G.G.,Crespo-Lopez, M. E.,Moran-Moguel, C.,Garcia, J. J.,Reiter,R. J., andAcuna-Castroviejo, D. (2001). Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol. Lett. 22: 101-108.
Pai, B. N.,Janakiramaiah, N.,Gangadhar, B. N., andRavindranath, V. (1994). Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol. Psychiatry 36: 489-491.
Post, A.,Holsboer, F., andBehl, C. (1998). Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: Suppression of NF-kappaB and neuroprotection by antioxidants. J. Neurosci. 18: 8236-8246.
Rao,M. L.,Gross, G.,Strebel, B.,Braunig, P.,Huber, G., andKlosterkotter, J. (1990). Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res. 34: 243-257.
Reiter, R. J. (1991). Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12: 151-180.
Reppert, S. M. (1997). Melatonin receptors: Molecular biology of a new family of G protein-coupled receptors. J. Biol. Rhythms 12: 528-531.
Rivest, R. W.,Aubert, M. L.,Lang, U., andSizonenko, P. C. (1986). Puberty in the rat: Modulation by melatonin and light. J. Neural. Transm. Suppl. 21: 81-108.
Rousseau, A.,Petren, S.,Plannthin, J.,Eklundh, T., andNordin, C. (1999). Serum and cerebrospinal fluid concentrations of melatonin:Apilot study in healthy male volunteers. J. Neural.Transm. 106: 883-888.
Schapira, A. H. (2001). Causes of neuronal death in Parkinson's disease. Adv. Neurol. 86: 155-162.
Shamir, E.,Barak, Y.,Plopsky, I.,Zisapel, N.,Elizur, A., andWeizman, A. (2000). Is melatonin treatment effective for tardive dyskinesia? J. Clin. Psychiatry 61: 556-558.
Shamir, E.,Barak, Y.,Shalman, I.,Laudon, M.,Zisapel, N.,Tarrasch, R.,Elizur, A., andWeizman, R. (2001). Melatonin treatment for tardive-dyskinesia: A double-blind placebo-controlled cross-over study. Arch. Gen. Psychiatry 58: 1049-1052.
Shieh, K. R.,Chu, Y. S., andPan, J. T. (1997). Circadian change of dopaminergic neuron activity: Effects of constant light and melatonin. Neuroreport 8: 2283-2287.
Tenn, C. C., andNiles, L. P. (1997). Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology 36: 1659-1663.
Tosini, G., andDirden, J. C. (2000). Dopamine inhibits melatonin release in the mammalian retina: In vitro evidence. Neurosci. Lett. 286: 119-122.
Vigano, D.,Lissoni, P.,Rovelli, F.,Roselli, M. G.,Malugani, F.,Gavazzeni, C.,Conti, A., andMaestroni, G. (2001). A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuroendocrinol. Lett. 22: 137-141.
Viguie, C.,Thibault, J.,Thiery, J. C.,Tillet, Y., andMalpaux, B. (1997). Characterization of the short dayinduced decrease in median eminence tyrosine hydroxylase activity in the ewe: Temporal relationship to the changes in luteinizing hormone and prolactin secretion and short day-like effect of melatonin. Endocrinology 138: 499-506.
Waldhauser, F.,Boepple, P. A.,Schemper, M.,Mansfield, M. J., andCrowley, W. F., Jr. (1991). Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J. Clin. Endocrinol. Metab. 73: 793-796.
Waldhauser, F.,Waldhauser, M.,Lieberman, H. R.,Deng,M. H.,Lynch, H. J.,andWurtman, R. J. (1984). Bioavailability of oral melatonin in humans. Neuroendocrinology 39: 307-313.
Weaver, D. R.,Liu, C., andReppert, S. M. (1996). Nature's knockout: The Mel1b receptor is not necessary for reproductive and circadian responses to melatonin in Siberian hamsters. Mol. Endocrinol. 10: 1478-1487.
Willis, G. L., andArmstrong, S. M. (1999). A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. 66: 785-795.
Young, S. N. (1996). Melatonin, sleep, aging, and the health protection branch. J. Psychiatry Neurosci. 21: 161-164.
Zimmermann, R. C.,Krahn, L. E.,Klee, G. G.,Ditkoff, E. C.,Ory, S. J., andSauer, M. V. (2001). Prolonged inhibition of presynaptic catecholamine synthesis with alpha-methyl-para-tyrosine attenuates the circadian rhythm of human TSH secretion. J. Soc. Gynecol. Invest. 8: 174-178.
Zisapel, N. (1999). The use of melatonin for the treatment of insomnia. Biol. Signals Recept. 8: 84-89.
Zisapel, N. (2001). Circadian rhythm sleep disorders: Pathophysiology and potential approaches to management. CNS Drugs 15: 311-428.
Zisapel, N.,Egozi, Y., andLaudon, M. (1982). Inhibition of dopamine release by melatonin: Regional distribution in the rat brain. Brain Res. 246: 161-163.
Zisapel, N.,Egozi, Y., andLaudon, M. (1985). Circadian variations in the inhibition of dopamine release from adult and newborn rat hypothalamus by melatonin. Neuroendocrinology 40: 102-108.
Zisapel, N., andLaudon, M. (1982). Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro: Inhibition by melatonin. Biochem. Biophys. Res. Commun. 104: 1610-1616.
Zisapel, N., andLaudon, M. (1983). Inhibition by melatonin of dopamine release from rat hypothalamus: Regulation of calcium entry. Brain Res. 272: 378-381.
Zisapel, N.,Nir, I., andLaudon, M. (1988). Circadian variations in melatonin-binding sites in discrete areas of the male rat brain. FEBS Lett. 232: 172-176.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zisapel, N. Melatonin–Dopamine Interactions: From Basic Neurochemistry to a Clinical Setting. Cell Mol Neurobiol 21, 605–616 (2001). https://doi.org/10.1023/A:1015187601628
Issue Date:
DOI: https://doi.org/10.1023/A:1015187601628